Skip to main content
. Author manuscript; available in PMC: 2018 Apr 15.
Published in final edited form as: Clin Cancer Res. 2016 Sep 27;23(8):1967–1973. doi: 10.1158/1078-0432.CCR-16-1224

Table 1.

Summary of biomarker measures.

Marker COU-AA-301 study (N = 644) ELM-PC4 study (N = 908)

Median (Range) Median (Range)
Baseline albumin 4.1 (2.9–4.9) 4.4 (2.5–5.4)
Baseline ALK 114.5 (33–4617) 96.0 (35–3,281)
Baseline CTC 4.0 (0–100) 2.0 (0–5,153)
Baseline hemoglobin 12.0 (7.3–16.5) 12.9 (4.7–17.5)
Baseline LDH 215.0 (84–3,373) 186.0 (67–1,868)
Baseline PSA 119.2 (0.4–10,110) 49.7 (1.7–3,906)
Week 13 CTC 1.0 (0–100) 0 (0–1,635)
Week 13 PSA 97.5 (0.1–8,582) 31.6 (0–7682)
Age 70 (42–95) 71 (49–89)

Abbreviations: ALK, alkaline phosphatase; CTC, circulating tumor cells; LDH, lactate dehydrogenase; PSA, prostate-specific antigen.